Back to top
more

Karyopharm Therapeutics (KPTI)

(Delayed Data from NSDQ)

$0.96 USD

0.96
474,671

+0.01 (1.43%)

Updated Jul 25, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Analysts Estimate Karyopharm Therapeutics (KPTI) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -10.00% and -12.23%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -1.72% and -0.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm's (KPTI) Xpovio Gets FDA Nod for Second-Line Myeloma

by Zacks Equity Research

Karyopharm (KPTI) gets FDA approval for label expansion of its marketed drug, Xpovio, in combination with Takeda's Velcade and dexamethasone for treating multiple myeloma in second-line setting.

Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 0.00% and -0.08%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Karyopharm Therapeutics (KPTI) Q3 Earnings Expected to Decline

by Zacks Equity Research

Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Karyopharm Therapeutics (KPTI) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Karyopharm Therapeutics (KPTI) stock based on the movements in the options market lately.

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -10.53% and 19.57%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Karyopharm Therapeutics (KPTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Karyopharm's Xpovio Gets FDA Accelerated Approval for DLBCL

by Zacks Equity Research

Karyopharm (KPTI) gets FDA approval for label expansion of its marketed drug, Xpovio, in relapsed or refractory diffuse large B-cell lymphoma.

Karyopharm Starts Dosing in Selinexor Study for Glioblastoma

by Zacks Equity Research

Karyopharm (KPTI) commences a phase I/II study evaluating Xpovio (selinexor) in combination with standard-of-care therapy in patients with newly-diagnosed or recurrent glioblastoma.

Are Options Traders Betting on a Big Move in Karyopharm Therapeutics (KPTI) Stock?

by Zacks Equity Research

Investors need to pay close attention to Karyopharm Therapeutics (KPTI) stock based on the movements in the options market lately.

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -11.43% and -15.99%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Why Karyopharm (KPTI) Might Surprise This Earnings Season

by Zacks Equity Research

Karyopharm (KPTI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Top Ranked Momentum Stocks to Buy for April 30th

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, April 30th.

What Makes Karyopharm Therapeutics (KPTI) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Karyopharm Therapeutics (KPTI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Karyopharm Starts Dosing With Selinexor for Coronavirus Infection

by Zacks Equity Research

Karyopharm (KPTI) doses the first patient in a phase II study evaluating the low dose of its drug Xpovio (selinexor) to treat hospitalized patients with severe COVID-19 infection. Shares up.

    Karyopharm (KPTI): Strong Industry, Solid Earnings Estimate Revisions

    by Zacks Equity Research

    Karyopharm (KPTI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

    Company News for Mar 3, 2020

    by Zacks Equity Research

    Companies in the news are: FTSV, MINI, KPTI ATEC

    Do Options Traders Know Something About Karyopharm (KPTI) Stock We Don't?

    by Zacks Equity Research

    Investors need to pay close attention to Karyopharm (KPTI) stock based on the movements in the options market lately.

    What's in Store for AstraZeneca (AZN) This Earnings Season?

    by Zacks Equity Research

    AstraZeneca's (AZN) fourth-quarter results are expected to reflect the impact of new drug sales.

    What's in Store for Acorda (ACOR) This Earnings Season?

    by Zacks Equity Research

    During Acorda's (ACOR) Q4 earnings call, investor focus will be on the sales uptake of its newly-launched Parkinson's disease drug Inbrija.

    What's in Store for Ironwood (IRWD) This Earnings Season?

    by Zacks Equity Research

    Ironwood Pharmaceuticals' (IRWD) Linzess is likely to have driven total revenues in the fourth quarter.

    Options Traders Expect Huge Moves in Karyopharm (KPTI) Stock

    by Zacks Equity Research

    Investors need to pay close attention to Karyopharm (KPTI) stock based on the movements in the options market lately.

    BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU

    by Zacks Equity Research

    The European Commission bestows an orphan drug status on BioLineRx's (BLRX) lead candidate Motixafortide, currently being evaluated with Merck's Keytruda to treat pancreatic cancer. Stock up.